Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Petracca

Showing results (91-100 of 140) with videos related to

Pageof 14
Sort By:
European Journal of Neurology|October 25, 2021
Cerebellar pathology and disability worsening in relapsing-remitting multiple sclerosis: A retrospective analysis from the CombiRx trialMaria Petracca, Gary Cutter, Sirio Cocozza, et al.
Multiple Sclerosis and Related Disorders|June 30, 2026
Real-world analytical and clinical evaluation of the Siemens Atellica® immunoassay for plasma neurofilament light chain in multiple sclerosisValerio Nicolella, Carmela Polito, Vincenzo Criscuolo, et al.
European Journal of Neurology|October 30, 2024
Association between CD20<sup>+</sup> T lymphocytes and neuropsychological findings in multiple sclerosisAntonio Esposito, Fabrizia Falco, Giulia Scalia, et al.
Multiple Sclerosis and Related Disorders|November 7, 2025
Anti-EBV antibody reduction during ocrelizumab treatment is not associated with multiple sclerosis outcomesAntonio Esposito, Luca Corsaro, Ilaria Delle Cave, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2025
Dysarthria assessment in multiple sclerosis patientsDavide Ranucci, Fabrizia Falco, Valerio Nicolella, et al.
Toxins|November 10, 2022
Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple SclerosisFederica Novarella, Antonio Carotenuto, Paolo Cipullo, et al.
Multiple Sclerosis and Related Disorders|April 29, 2022
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosisEmanuela Zappulo, Antonio Riccardo Buonomo, Marcello Moccia, et al.
AJNR. American Journal of Neuroradiology|July 3, 2025
Predicting Ten-Year Clinical Outcomes in Multiple Sclerosis with Radiomics-Based Machine Learning ModelsMario Tranfa, Maria Petracca, Renato Cuocolo, et al.
European Radiology|March 14, 2022
Stratification of multiple sclerosis patients using unsupervised machine learning: a single-visit MRI-driven approachGiuseppe Pontillo, Simone Penna, Sirio Cocozza, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 1, 2020
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosisEdward Fox, Amy E Lovett-Racke, Matthew Gormley, et al.
Pageof 14

Showing results (91-100 of 140) with videos related to

Sort By:
Pageof 14
European Journal of Neurology|October 25, 2021
Cerebellar pathology and disability worsening in relapsing-remitting multiple sclerosis: A retrospective analysis from the CombiRx trialMaria Petracca, Gary Cutter, Sirio Cocozza, et al.
Multiple Sclerosis and Related Disorders|June 30, 2026
Real-world analytical and clinical evaluation of the Siemens Atellica® immunoassay for plasma neurofilament light chain in multiple sclerosisValerio Nicolella, Carmela Polito, Vincenzo Criscuolo, et al.
European Journal of Neurology|October 30, 2024
Association between CD20<sup>+</sup> T lymphocytes and neuropsychological findings in multiple sclerosisAntonio Esposito, Fabrizia Falco, Giulia Scalia, et al.
Multiple Sclerosis and Related Disorders|November 7, 2025
Anti-EBV antibody reduction during ocrelizumab treatment is not associated with multiple sclerosis outcomesAntonio Esposito, Luca Corsaro, Ilaria Delle Cave, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2025
Dysarthria assessment in multiple sclerosis patientsDavide Ranucci, Fabrizia Falco, Valerio Nicolella, et al.
Toxins|November 10, 2022
Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple SclerosisFederica Novarella, Antonio Carotenuto, Paolo Cipullo, et al.
Multiple Sclerosis and Related Disorders|April 29, 2022
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosisEmanuela Zappulo, Antonio Riccardo Buonomo, Marcello Moccia, et al.
AJNR. American Journal of Neuroradiology|July 3, 2025
Predicting Ten-Year Clinical Outcomes in Multiple Sclerosis with Radiomics-Based Machine Learning ModelsMario Tranfa, Maria Petracca, Renato Cuocolo, et al.
European Radiology|March 14, 2022
Stratification of multiple sclerosis patients using unsupervised machine learning: a single-visit MRI-driven approachGiuseppe Pontillo, Simone Penna, Sirio Cocozza, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 1, 2020
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosisEdward Fox, Amy E Lovett-Racke, Matthew Gormley, et al.
Pageof 14